Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Artigo
|
Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 CountriesGammie, Todd ; Lu, Christine Y ; Babar, Zaheer Ud-Din Garattini, SilvioPloS one, 2015-10, Vol.10 (10), p.e0140002-e0140002 [Periódico revisado por pares]United States: Public Library of ScienceTexto completo disponível |
|
2 |
Material Type: Artigo
|
Socio-economic burden of rare diseases: A systematic review of cost of illness evidenceAngelis, Aris ; Tordrup, David ; Kanavos, PanosHealth policy (Amsterdam), 2015-07, Vol.119 (7), p.964-979 [Periódico revisado por pares]Ireland: Elsevier Ireland LtdTexto completo disponível |
|
3 |
Material Type: Artigo
|
Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision FrameworkPaulden, Mike ; Stafinski, Tania ; Menon, Devidas ; McCabe, ChristopherPharmacoEconomics, 2015-03, Vol.33 (3), p.255-269 [Periódico revisado por pares]Cham: Springer International PublishingTexto completo disponível |
|
4 |
Material Type: Artigo
|
Rare diseases and effective treatments: are we delivering?Luzzatto, Lucio ; Hollak, Carla E M ; Cox, Timothy M ; Schieppati, Arrigo ; Licht, Christoph ; Kääriäinen, Helena ; Merlini, Giampaolo ; Schaefer, Franz ; Simoens, Steven ; Pani, Luca ; Garattini, Silvio ; Remuzzi, GiuseppeThe Lancet (British edition), 2015-02, Vol.385 (9970), p.750-752 [Periódico revisado por pares]England: Elsevier LtdTexto completo disponível |
|
5 |
Material Type: Artigo
|
Estimating the budget impact of orphan medicines in Europe: 2010 - 2020Schey, Carina ; Milanova, Tsveta ; Hutchings, AdamOrphanet journal of rare diseases, 2011-09, Vol.6 (1), p.62-62, Article 62 [Periódico revisado por pares]England: BioMed Central LtdTexto completo disponível |
|
6 |
Material Type: Artigo
|
Estimating the clinical cost of drug development for orphan versus non-orphan drugsJayasundara, Kavisha ; Hollis, Aidan ; Krahn, Murray ; Mamdani, Muhammad ; Hoch, Jeffrey S ; Grootendorst, PaulOrphanet journal of rare diseases, 2019-01, Vol.14 (1), p.12-12, Article 12 [Periódico revisado por pares]England: BioMed Central LtdTexto completo disponível |
|
7 |
Material Type: Artigo
|
Societal Preferences for Funding Orphan Drugs in the United Kingdom: An Application of Person Trade-Off and Discrete Choice Experiment MethodsBourke, Siobhan M. ; Plumpton, Catrin O. ; Hughes, Dyfrig A.Value in health, 2018-05, Vol.21 (5), p.538-546 [Periódico revisado por pares]United States: Elsevier IncTexto completo disponível |
|
8 |
Material Type: Artigo
|
Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?Hughes-Wilson, Wills ; Palma, Ana ; Schuurman, Ad ; Simoens, StevenOrphanet journal of rare diseases, 2012-09, Vol.7 (1), p.74-74 [Periódico revisado por pares]England: BioMed CentralTexto completo disponível |
|
9 |
Material Type: Artigo
|
Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?Rodriguez-Monguio, R ; Spargo, T ; Seoane-Vazquez, EOrphanet journal of rare diseases, 2017-01, Vol.12 (1), p.1-1, Article 1 [Periódico revisado por pares]England: BioMed CentralTexto completo disponível |
|
10 |
Material Type: Artigo
|
Do investors value the FDA orphan drug designation?Miller, Kathleen LOrphanet journal of rare diseases, 2017-06, Vol.12 (1), p.114-114, Article 114 [Periódico revisado por pares]England: BioMed Central LtdTexto completo disponível |